Related Experiment Video
Updated: Aug 12, 2026
Transient Expression of Proteins by Hydrodynamic Gene Delivery in Mice
Published on: May 5, 2014
Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for
S A Chalew1, M Phillip, A A Kowarski
1Division of Pediatric Endocrinology, University of Maryland School of Medicine, Baltimore 21201.
Insights
Recombinant growth hormone therapy significantly increases growth hormone levels and insulin secretion in children with growth deficiency. These hormonal changes may be relevant for patients with insulin resistance or those on higher growth hormone doses.
Area of Science:
- Pediatric Endocrinology
- Pharmacokinetics
- Metabolic Studies
Background:
- Growth hormone (GH) therapy is crucial for children with GH deficiency and poor linear growth.
- Understanding the pharmacokinetic and metabolic effects of standard GH doses is essential for optimizing treatment.
Purpose of the Study:
- To evaluate the impact of a standard dose of injected recombinant human growth hormone (rhGH) on integrated GH and insulin concentrations.
- To assess the pharmacokinetic profile of rhGH after subcutaneous injection in pediatric patients.
Main Methods:
- A cohort of 12 growth hormone-deficient children received subcutaneous rhGH (0.06 mg/kg) three times weekly.
- Integrated GH and insulin concentrations were measured before therapy and at 6 months post-initiation, specifically during a GH injection day.
Main Results:
- Post-treatment integrated GH concentrations were significantly elevated compared to pre-treatment levels and those in normally growing children (P < .001).
- Pharmacokinetic analysis revealed a peak GH level of 53.7 ± 24.1 µg/L with a half-life of 3.0 ± 0.7 hours.
- Integrated insulin concentrations significantly increased after rhGH injection (33.4 ± 9.5 mU/L) compared to baseline (19.0 ± 10.9 mU/L; P < .0008).
Conclusions:
- Standard rhGH injections lead to substantially higher integrated GH levels than observed in healthy children, accompanied by increased insulin secretion.
- The observed hormonal shifts may have clinical implications for pediatric patients with insulin resistance or those requiring higher rhGH dosages.
Objective:
To evaluate the effect of a standard dose of injected recombinant growth hormone on the integrated concentrations of growth hormone and insulin.
Design:
Integrated concentrations were studied in patients receiving growth hormone therapy before and on the day of injection.
Setting:
Pediatric endocrine clinic and diagnostic unit.
Patients:
Twelve growth hormone-deficient patients with poor linear growth and deficient growth hormone response to provocative stimulation and/or 24-hour integrated concentration.
Intervention:
Patients received subcutaneous injections of 0.06 mg/kg of growth hormone three times a week in the evenings at approximately 8 PM. Integrated concentrations were measured again approximately 6 months after the start of therapy at the time of a growth hormone injection.
Measurements And Results:
Mean growth hormone dose administered was 2.0 +/- 0.5 mg. Integrated concentration of growth hormone was 2.2 +/- 0.9 micrograms/L before therapy. The integrated concentration of growth hormone after treatment (14.6 +/- 4.2 micrograms/L) was significantly higher than that before treatment and that of normally growing children (P < .001). After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area). There was no relationship between integrated concentration of growth hormone or pharmacokinetic variables after treatment and the growth response to 6 months' therapy. Integrated concentration of insulin before treatment was 19.0 +/- 10.9 mU/L, which was significantly lower than that after injection of growth hormone (33.4 +/- 9.5 mU/L; n = 9, P < .0008).
Conclusions:
Integrated concentrations of growth hormone after an injection of 0.06 mg/kg of growth hormone are considerably higher than spontaneous integrated concentrations of growth hormone observed in normally growing children, and associated with a rise in insulin secretion. These changes may be pertinent in patients with underlying insulin resistance or when higher doses of growth hormone are used for therapy.
Related Concept Videos
01:09Recombinant DNA
01:24Dosage Regimen: Individualization
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...